All studies
Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence StudyInterventional
Bioequivalence study between two fluticasone propionate 250μg/salmeterol 50μg inhalation powders
At a glance
Status
Ongoing, recruiting
Phase
Human Pharmacology (Phase I)- Bioequivalence Study
Sponsor
Respirent Pharmaceuticals Co. Ltd.
Enrolment target
34
Start
26 Jul 2023
Healthy volunteers.Regular treatment of bronchial asthmawhere a combination
product containing a corticosteroid and a long-acting beta2-adrenergic
agonist (LABA) is indicated for:
•Twice-daily treatment of asthma in patients aged 4 years and older.
•Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (1)
- —Greece
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.